The majority (48%) of stem cell-based products in advanced stage of clinical trials are for the treatment of cardiovascular diseases, including cardiac diseases, stroke and peripheral arterial disease.

Total of 21 companies have stem cell-based R & D products in advanced stage of development, with 8 of them from the USA and 7 from Europe. This difference between the USA and European companies is very narrow and reflects highly progressive development of stem cell-based products in Europe, where Germany and Spain are the leading countries in this field.

Key Topics Covered:

1. Pipeline Analysis

2. Product Profiles

3. Companies and Investors

4. Company Profiles

List of Tables:

Table 1. Products in Development and Clinical Trials Schedule

Table 2. Type and Sources of Stem Cells

Table 3. Companies and Investors

researchandmarkets